​

Arcturus Therapeutics (ARCT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Arcturus Therapeutics Revenue Highlights

Latest Revenue (Y)

$152.31M

Latest Revenue (Q)

$38.81M

Main Segment (Y)

Collaboration Revenue

Main Geography (Y)

Foreign Countries

Arcturus Therapeutics Revenue by Period

Arcturus Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$152.31M-3.45%
2023-12-31$157.75M-23.33%
2022-12-31$205.75M1564.82%
2021-12-31$12.36M29.56%
2020-12-31$9.54M-54.12%
2019-12-31$20.79M31.97%
2018-12-31$15.75M21.20%
2017-12-31$13.00M-36.23%
2016-12-31$20.38M232.06%
2015-12-31$6.14M100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31--

Arcturus Therapeutics generated $152.31M in revenue during NA 2024, up -3.45% compared to the previous quarter, and up 732.65% compared to the same period a year ago.

Arcturus Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$38.81M-15.58%
2024-06-30$45.98M41.04%
2024-03-31$32.60M15.55%
2023-12-31$28.21M-34.96%
2023-09-30$43.38M353.49%
2023-06-30$9.56M-88.00%
2023-03-31$79.73M-50.18%
2022-12-31$160.05M1097.17%
2022-09-30$13.37M-50.66%
2022-06-30$27.09M416.65%
2022-03-31$5.24M-9.49%
2021-12-31$5.79M137.75%
2021-09-30$2.44M21.79%
2021-06-30$2.00M-5.92%
2021-03-31$2.13M-4.96%
2020-12-31$2.24M-4.07%
2020-09-30$2.33M0.47%
2020-06-30$2.32M-12.24%
2020-03-31$2.65M-10.85%
2019-12-31$2.97M-10.55%
2019-09-30$3.32M-67.32%
2019-06-30$10.15M133.40%
2019-03-31$4.35M-42.59%
2018-12-31$7.58M121.36%
2018-09-30$3.42M43.46%
2018-06-30$2.39M0.80%
2018-03-31$2.37M-81.79%
2017-12-31$13.00M294.36%
2017-09-30$3.30M-12.36%
2017-06-30$3.76M-2.08%
2017-03-31$3.84M100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30--

Arcturus Therapeutics generated $38.81M in revenue during Q3 2024, up -15.58% compared to the previous quarter, and up 405.80% compared to the same period a year ago.

Arcturus Therapeutics Revenue Breakdown

Arcturus Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22
Collaboration Revenue$138.39M$157.75M$205.75M
Grant$13.92M--

Arcturus Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (90.86%), and Grant (9.14%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Jun 19
Collaboration Revenue$21.00M$38.81M$45.98M$32.60M$78.02M$79.73M--
Grant$1.77M$2.86M$3.88M$5.41M$954.00K$556.00K--
Other Collaboration Revenue-------$3.60M

Arcturus Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (92.24%), and Grant (7.76%).

Arcturus Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24
Foreign Countries$138.40M

Arcturus Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: Foreign Countries (100.00%).

Arcturus Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BPMCBlueprint Medicines$508.82M$128.18M
MDGLMadrigal Pharmaceuticals$180.13M$62.17M
ARCTArcturus Therapeutics$152.31M$38.81M
DAWNDay One Biopharmaceuticals$131.16M$20.07M
GOSSGossamer Bio$114.70M$9.48M
ACLXArcellx$107.94M$26.03M
AMLXAmylyx Pharmaceuticals$87.37M$416.00K
CRSPCRISPR Therapeutics$37.31M$602.00K
STOKStoke Therapeutics$36.55M$4.89M
FATEFate Therapeutics$13.63M$6.77M
NTLAIntellia Therapeutics-$9.11M
ETNB89bio--
AKROAkero Therapeutics--
BDTXBlack Diamond Therapeutics--
FDMT4D Molecular Therapeutics--
CRBUCaribou Biosciences-$3.46M
BEAMBeam Therapeutics-$14.27M
PLRXPliant Therapeutics--
BMEABiomea Fusion--

ARCT Revenue FAQ

What is Arcturus Therapeutics’s yearly revenue?

Arcturus Therapeutics's yearly revenue for 2024 was $152.31M, representing a decrease of -3.45% compared to 2023. The company's yearly revenue for 2023 was $157.75M, representing a decrease of -23.33% compared to 2022. ARCT's yearly revenue for 2022 was $205.76M, representing an increase of 1564.82% compared to 2021.

What is Arcturus Therapeutics’s quarterly revenue?

Arcturus Therapeutics's quarterly revenue for Q3 2024 was $38.82M, a -15.58% decrease from the previous quarter (Q2 2024), and a -10.52% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $45.98M, a 41.04% increase from the previous quarter (Q1 2024), and a 380.67% increase year-over-year (Q2 2023). ARCT's quarterly revenue for Q1 2024 was $32.6M, a 15.55% increase from the previous quarter (Q4 2023), and a -59.11% decrease year-over-year (Q1 2023).

What is Arcturus Therapeutics’s revenue growth rate?

Arcturus Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -25.98%, and for the last 5 years (2020-2024) was 1496.71%.

What are Arcturus Therapeutics’s revenue streams?

Arcturus Therapeutics's revenue streams in c 24 are Collaboration Revenue, and Grant. Collaboration Revenue generated $138.39M in revenue, accounting 90.86% of the company's total revenue, down -12.27% year-over-year. Grant generated $13.92M in revenue, accounting 9.14% of the company's total revenue

What is Arcturus Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Arcturus Therapeutics was Collaboration Revenue. This segment made a revenue of $138.39M, representing 90.86% of the company's total revenue.